Antonio Benedetti
Direttore/Membro del Consiglio presso Cycle Pharmaceuticals Ltd.
Profilo
Antonio Benedetti has worked as a Director at Cycle Pharmaceuticals Ltd.
since 2016.
Posizioni attive di Antonio Benedetti
Società | Posizione | Inizio |
---|---|---|
Cycle Pharmaceuticals Ltd.
Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Direttore/Membro del Consiglio | 25/01/2016 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Cycle Pharmaceuticals Ltd.
Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Health Technology |
- Borsa valori
- Insiders
- Antonio Benedetti